GSK2636771

DRUG4 trials

Sponsors

GlaxoSmithKline, Yonsei University, M.D. Anderson Cancer Center

Conditions

Advanced Gastric AdenocarcinomaCancerMelanoma and Other Malignant Neoplasms of SkinMetastatic MelanomaNeoplasms

Phase 1

A Phase I/IIa, First Time in Human, Study of GSK2636771 in Subjects With Advanced Solid Tumors With Phosphatase and Tensin Homolog (PTEN) Deficiency

CompletedNCT01458067

GlaxoSmithKlineCancer

Start: 2011-11-10End: 2016-02-25Updated: 2018-07-24

Dose-finding Study of GSK2636771 When Administered in Combination With Enzalutamide in Male Subjects With Metastatic Castration-Resistant Prostate Cancer

CompletedNCT02215096

GlaxoSmithKlineNeoplasms

Start: 2014-11-13End: 2019-10-03Updated: 2020-10-22

PI3Kβ Selective Inhibitor With Paclitaxel, Advanced Gastric Adenocarcinoma

CompletedNCT02615730

Yonsei UniversityAdvanced Gastric Adenocarcinoma

Start: 2016-02-29End: 2021-03-31Updated: 2025-01-24

Study of the Selective PI3K-Beta Inhibitor GSK2636771 in Combination With Pembrolizumab in Patients With Metastatic Melanoma and PTEN Loss

CompletedNCT03131908

M.D. Anderson Cancer CenterMelanoma and Other Malignant Neoplasms of Skin, Metastatic Melanoma

Start: 2017-07-17End: 2026-08-20Updated: 2026-08-27

Related Papers

Phase I/II study of the selective PI3Kβ inhibitor GSK2636771 in combination with pembrolizumab in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and PTEN loss.

Journal of Clinical Oncology2022-06-0111 citations

Genomic profiling as a response predictor of second-line treatment in advanced gastric cancer patients: Post-hoc analyses of two phase Ib/II trials.

Journal of Clinical Oncology2022-01-19

A Phase I, Open-Label, Dose-Finding Study of GSK2636771, a PI3Kβ Inhibitor, Administered with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer

Clinical Cancer Research2021-07-1931 citations

Safety results from phase I/II study of the PI3Kβ inhibitor GSK2636771 (G) in combination with pembrolizumab (P) in patients (pts) with PD-1 refractory metastatic melanoma (MM) and PTEN loss.

Journal of Clinical Oncology2020-05-208 citations

Phase I/II study of the PI3Kβ inhibitor GSK2636771 in combination with pembrolizumab (P) in patients (pts) with PD-1 refractory metastatic melanoma (MM) and PTEN loss.

Journal of Clinical Oncology2018-05-2012 citations

A phase I/II, first-in-human dose-escalation study of GSK2636771 in patients (pts) with PTEN-deficient advanced tumors.

Journal of Clinical Oncology2014-05-2027 citations